Compare Entegris Inc (ENTG) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Enveric Biosciences Inc — how do they compare? Entegris Inc trades at $134.37 (market cap $21.12B), while Enveric Biosciences Inc trades at $1.39 (market cap $5.32M). The key difference: Entegris Inc is far larger — about 3969.9× Enveric Biosciences Inc's market cap, and Entegris Inc pays a 0.29% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENTG | ENVB | |
|---|---|---|
Market Cap | $21.12B | $5.32M |
Sector | Technology | Health |
52-Week High | $184.00 | $17.40 |
52-Week Low | $68.80 | $1.28 |
Enterprise Value | $24.44B | $408.82K |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $140.63, up 3.2% on the day, with a bearish technical signal and premium valuation metrics. The company reported strong Q1 2026 earnings, beating estimates, and maintains a solid cash flow position. Recent news highlights a quarterly dividend declaration and a non-exclusive cross-licensing agreement for EUV lithography technology.
The outlook is mixed: Wall Street analysts maintain a bullish consensus with a $178.40 price target (26.9% upside), citing AI-driven semiconductor demand as a catalyst. However, risks include elevated valuation multiples, competitive pressures in the semiconductor materials sector, and execution challenges in maintaining recent earnings momentum.
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
